Category: Pharma Industry

AmeriSourceBergen Has Resumed Distributing 340B-Priced Bausch Health Drugs

February 2, 2021 Tom Mirga, Editor at Large Views

340B pricing on Bausch Health products is being restored to AmeriSourceBergen's ordering platforms, 340B Report has learned. | Source: Shutterstock

Drug manufacturer Bausch Health and distributor AmeriSourceBergen Corp. (ABC) apparently have settled their differences and 340B pricing on Bausch Health products is being restored to ABC’s ordering platforms, 340B Report has learned.

Bausch Health blindsided 340B covered entities on

…

Generic Liquid Drug Manufacturer Providing Refunds for 340B Overcharges

January 28, 2021 Tom Mirga, Editor at Large Views

The U.S. Health Resources and Services Administration (HRSA) is requiring Pharmaceutical Associates, Inc. (PAI), a South Carolina-based generic liquid drug manufacturer, to repay 340B covered entities for charges on its products above the 340B ceiling price discovered during a fiscal

…

Drug Company Eton Posts 340B Limited Distribution Notice

January 28, 2021 Tom Mirga, Editor at Large Views

Illinois-based Eton Pharmaceuticals is making its Alkindi Sprinkle hydrocortisone product available through a sole specialty distributor “to ensure that patients…receive appropriate drug and clinical counseling and to support therapeutic adherence,” the company informed 340B covered entities in a Jan. 12

…

Gilead Adjusts Planned Change in its Patient Assistance After HIV Community Pushes Back

January 19, 2021 Tom Mirga, Editor at Large Views

NASTAD and others in the HIV community said they raised their concerns with Gilead about its planned change to its patient assistance program, and the company appears to have listened. | Source: Shutterstock

Drug manufacturer Gilead has altered a planned change to its patient assistance program (PAP) for uninsured people living with HIV that would have been unworkable for some vulnerable patients, HIV/AIDS caregivers and activists say. The change also would have deprived

…

HHS Asks Court to Toss Out Hospitals’ 340B Contract Pharmacy Lawsuit

January 19, 2021 Tom Mirga, Editor at Large Views

The lawsuit against HHS by 340B hospitals is just one of several underway over drug manufacturers’ denials of 340B pricing on drugs dispensed by contract pharmacies. | Source: Shutterstock

Outgoing U.S. Health and Human Services (HHS) Secretary Alex Azar last week asked a federal district judge to dismiss a lawsuit against him and his department by 340B hospitals over HHS’s enforcement of its 340B contract pharmacy requirements for drug

…

Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions

January 19, 2021 Tom Mirga, Editor at Large Views

HHS has for the second time delayed the effective date of a Trump administration rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The new date is July 20. | Shutterstock

U.S. insulin manufacturer and pharmacy benefit manager (PBM) business practices “have created a vicious cycle of price increases that have sent costs for patients and taxpayers through the roof,” U.S. Senate Finance Committee leaders Chuck Grassley (R-Iowa) and Ron Wyden

…

340B Stakeholders Reconsider Campaign Contributions in Wake of Capitol Riot

January 19, 2021 Tom Mirga, Editor at Large Views

Businesses and groups involved in 340B are reconsidering their political donations following a pro-Trump mob's assault on the U.S. Capitol. | Source: Shutterstock

National health care organizations and businesses with major stakes in the 340B program have suspended political contributions following a pro-Trump mob’s Jan. 6 violent attack on Congress to stop it from counting and certifying the Electoral College’s votes for president.

…

Health Centers File 340B Dispute Resolution Petitions Against Drug Manufacturers

January 14, 2021 Tom Mirga, Editor at Large Views

The National Association of Community Health Centers (NACHC) last night on its members’ behalf asked a new federal 340B program administrative dispute resolution (ADR) panel to order drug manufacturers Eli Lilly and Co., Sanofi, and AstraZeneca to lift all “qualifications,

…

Lilly Asks Court to Shield it From “Crippling” 340B Sanctions

January 14, 2021 Tom Mirga, Editor at Large Views

Drug manufacturer Eli Lilly and Co. told a court this week that HHS has placed it in the "untenable position of offering 340B discounts that are not required by the statute or else facing crippling financial sanctions." | Source: Shutterstock

340B program stakeholders are still digesting drug manufacturers AstraZeneca, Eli Lilly and Co., and Sanofi’s Jan. 12 lawsuits to block federal sanctions over their decisions to stop or impose conditions on 340B discounts on drugs dispensed by contract pharmacies.

…

AstraZeneca, Lilly, and Sanofi Sue HHS to Block Requirement To Give 340B Discounts To Contract Pharmacies

January 13, 2021 Tom Mirga, Editor at Large Views

AstraZeneca, Eli Lilly and Co., and Sanofi sued HHS in defense of their 340B contract actions just hours before covered entities could begin challenging those actions in a new 340B administrative dispute resolution process. | Source: Shutterstock

In a major escalation of the fight over 340B contract pharmacy, drug manufacturer AstraZeneca late yesterday asked a federal court to declare that it “is not required to offer 340B discounts to contract pharmacies.”

As we went to press, we

…

Site Footer Live